Notably, PRMT5 has been implicated in mediating doxorubicin resistance in breast cancer [134], suggesting that combining PRMT5 inhibitors with chemotherapy could synergistically suppress breast cancer cell proliferation and growth [135]. Here, PRMT5 is linked to breast carcinoma.